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LONG-TERM SURVIVAL AND QUALITY OF LIFE (QOL) ASSESSMENT AF-
TER ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT) FOR ACUTE
LEUKEMIA AND MDS; COMPARABLE RESULTS WITH MYELOABLATIVE
AND REDUCED-INTENSITY CONDITIONING
Shimoni, A., Tallis, E., Rand, A., Shem-Tov, N., Volchek, Y.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel
Allogeneic SCT is a curative therapy for patients (pts) with acute
leukemia and MDS. SCT is associated with substantial mortality
during the first 2 years after SCT whereas after 2 years survival
curves often reach a plateau. The pattern of late events and QOL
was reported in myeloablative conditioning (MAC) but there is lim-
ited data in the reduced intensity (RIC) setting. We analyzed SCT
results in a cohort of 457 pts with acute leukemia and MDS. Pts
meeting standard eligibility criteria were given MAC (BuCy or Cy/
TBI)). Pts considered at excessive risk for non-relapse mortality
(NRM) were given reduced toxicity myeloablative conditioning
(RTC) such as fludarabine (F) with high-dose busulfan (Bu) or treo-
sulfan or RIC with F and reduced Bu. The 5-year overall survival
(OS) rate was 38% (95CI, 33-43); similar with the various regimens.
131 pts, median age 52 (17-72) were alive and leukemia-free 2 years
after SCT, with RIC (n5 41), RTC (n5 42) or MAC (n5 48). The
probability of remaining alive for the next 5 years was 81% (95CI,
71-90). OS was 75%, 87%, and 83%, respectively (p 5 NS). There
were 18 deaths beyond 2 years. 7 pts had NRM due to solid cancers
(n 5 2), myocardial infarction (n 5 2) and chronic GVHD (n 5 3);
cumulative incidence 7% (3-16). 11 pts died of relapse; cumulative
incidence 12% (7-23). Relapse risk was 16%, 9% and 6% beyond
2, 3 and 5 years after SCT, respectively. Advanced age (. 50) and co-
morbidity score . 2 at SCT correlated with shortened OS. OS was
70% and 93% in the older and younger groups, respectively (p 5
0.02). Chronic GVHD predicted reduced late relapse rate while ad-
vanced age predicted late NRM. The regimen used was not corre-
lated with any of these outcomes. QOL was assessed by the
EORTC QLQ-C30 questionnaire. Mean QOL score was 67, 67
and 68 after RIC, RTC and MAC, respectively. A low QOL score
(20 points lower than the median) was reported by 25%, 37% and
33%, respectively (p 5 NS). There was no difference in any of the
other domains of QOL assessment as well. Multiple regression anal-
ysis identified continuous need for immune suppressive therapy
(IST) and depression as factors correlated with a low score. Pts given
RIC/RTC had shorter duration of IST and were more likely to stop
it (78%, 73% and 62%, p5 0.06, respectively). This may be associ-
ated with better QOL. In conclusion the pattern of late outcome is
similar after MAC and RIC/RTC. Younger pts who are leukemia-
free 2 years after SCT can expect a good outcome and relatively
good QOL.LEUKEMIA
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STEM CELL TRANSPLANTATION
Tang, J.-L.1,2, Chou, S.-C.2, Hou, H.-A.2, Chen, C.-Y.2, Yao, M.2,
Ko, B.-S.2, Huang, S.-Y.2, Chou, W.-C.2,3, Tsay, W.2, Chen, Y.-C.2,3,
Tien, H.-F.2 1National Taiwan University, Taipei City, Taiwan,
Taiwan; 2National Taiwan University Hospital, Taipei City, Taiwan,
Taiwan; 3National Taiwan University Hospital, Taipei City, Taiwan,
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Several gene mutations have been shown to have clinical implica-
tions in patients with acute myeloid leukemia (AML). However, the
prognostic impact of gene mutations in AML patients receiving allo-
geneic hematopoietic stem cell transplantation (allo-HSCT) re-
mains unclear. We retrospectively evaluated the clinical
implication of 10 gene mutations in 325 adult AML patients; 100
of them received allo-HSCT and 225 did not. The genetic alter-ations analyzed included NPM1, FLT3-ITD, FLT3-TKD,
CEBPA, N-RAS, K-RAS, MLL-PTD, IDH1, AML1/RUNX1,
and WT1. In patients who did not receive allo-HSCT, older age,
higher WBC count, unfavorable karyotype, FLT3-ITD, and
AML1/RUNX1 mutation were significantly associated with poor
overall survival, while CEBPA mutation and NPM1mut/FLT3-
ITDneg were associated with good outcome in both univariate and
multivariate analyses. However, in allo-HSCT patients, preHSCT
disease status, karyotype, use of HLA-identical sibling donor,
CEBPA double mutation, and AML1/RUNX1 mutation were five
independent factors that affect post-HSCT overall survival (OS)
and relapse-free survival (RFS). The prognostic impacts of FLT3-
ITD and NPM1mut/FLT3-ITDneg were lost in AML patients re-
ceiving allo-HSCT. Interestingly, AML1/RUNX1 mutation had
a trend to be associated with good, rather than poor, prognosis in
this group of patients (p 5 0.073). The few patients with K-RAS
or WT1 mutation also had poor OS and RFS after HSCT. In con-
clusion, different types of gene mutations might have unique prog-
nostic impact on allo-HSCT outcome in AML patients. These
results need to be confirmed by further studies in more patients.LYMPHOMA/MULTIPLE MYELOMA
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MULTIPLE
MYELOMA
Bashir, Q.1, Wei, W.1, Chiattone, A.1, Rondon, G.1, Parmar, S.1,
Shah, N.1, Booc, E.H.1, Dinh, Y.1, Qureshi, S.1, Shah, J.1,
Orlowski, R.Z.1, Webber, D.1, Champlin, R.E.1, Giralt, S.2,
Qazilbash, M.H.1 1University of Texas M.D. Anderson Cancer Center,
Houston, TX; 2Memorial Sloan Kettering Cancer Center, New York, NY
Background: Allogeneic hematopoietic cell transplantation (allo
HCT) is a potentially curative therapy for multiple myeloma
(MM), but has high treatment-mortality (TRM). In addition, disease
relapse occurs in a significant number of patients.We sought to eval-
uate if the recent advances in the field of HCT and MM have im-
pacted the results of allo HCT for MM. We present the results of
allo HCT performed at a single center over last 25 years.
Methods: 149 patients withMMwho underwent alloHCTbetween
11/1985 and 6/2010 using myeloablative (MA) N 5 52, or reduced
intensity conditioning (RIC) N 5 97 at our institution were retro-
spectively analyzed.
Results: Patient characteristics and pertinent outcomes are summa-
rized in the Table. 62 (42%) were female.Median age was 50 (28-70)
years. Median follow up is 2.4 years [11.3 years for the patients who
received allo HCT prior to year 2000(\ 2000); 2 years for the pa-
tients who received allo HCT in the year 2000 and onwards ($
2000)]. TRM at 2 year was 37%. TRM was significantly lower for
year $ 2000, recipients of RIC regimens, recipients of peripheral
blood stem cells (HPC-A), and disease status at transplant PR or bet-
ter. There was no difference between TRM for patients above or be-
low age 50 years (p 0.08). Grade II-IV acute and limited or extensive
chronic graft-versus host disease was seen in 31%, and 37% patients,
respectively. Progression free survival (PFS) at 2 year and 5 year was
23% (95%CI: 16-30) and 15% (95%CI: 9-21), respectively. Overall
survival (OS) at 2 year and 5 year was 40% (95%CI: 32-48) and 21%
(95% CI: 13-29), respectively. At the time of last follow up 40 pa-
tients are still alive and 28 are in remissionn, longest for 166 months.
On univariate analysis the OS was significantly better for year $
2000 versus year\ 2000; recipients of HPC-A versus HPC-M; pri-
mary responsive disease versus relapse or primary refractory disease
at HCT; disease status at HCT PR or better; and patients without
poor risk cytogenetic features at diagnosis. OS was longer in patients
who received maintenance therapy post allo HCT (N 5 12) versus
the patients who did not, although it did not reach statistical signif-
icance (2.9 years versus 8.4 months; p 0.06).
Conclusions:AlloHCT forMMcan offer long term disease control
in a subset of MM patients. TRM has declined and outcomes have
significantly improved over the last decade. Maintenance therapy
may have a role post allo HCT.
